WHO Issues Warning Over Critical Shortage of Weight-Loss Medications

Under 10% of people eligible to benefit from weight-loss injections like Wegovy are able to get them, warns the World Health Organization as it issues its inaugural recommendations on the medications.

Given over a billion individuals worldwide currently obese, it is calling for more widespread and fairer availability to GLP-1 medication.

According to forecasts, more than two billion could be living with obesity by 2030 without intervention.

"Our new guidelines affirms that excess weight is a lifelong illness that can be addressed with holistic and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are significant hurdles to broad access to the jabs that can aid individuals in losing substantial weight, explains the body.

GLP-1 Therapy Scarcity

Even in the current best projected outlook, the production of these medications might only reach about 100 million people – under 10% of the global need, as stated by the health organization.

The guideline urges governments and firms to widen access, via approaches such as licensing agreements.

Exclusive production rights on a key compound – the primary component of the drug Wegovy – is set to lapse in a number of countries in 2026.

The Way Obesity Injections Function

These medications mimick a natural hormone to slow digestion, suppress the appetite and boost satiety so people consume fewer calories.

People typically begin shedding pounds in the initial weeks of starting on the regular doses.

Evidence points to users may put most of the weight back on a year later of stopping the medication, because their normal appetite return.

Being overweight or obese elevates your risk for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and some cancers.

Excess weight impacts people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.